The elevation of fibroblast growth factor 21 is associated with generalized periodontitis in patients with treated metabolic syndrome

Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 2007;5(6):426–37.

Google Scholar 

Patel R, Bookout AL, Magomedova L, Owen BM, Consiglio GP, Shimizu M, et al. Glucocorticoids regulate the metabolic hormone FGF21 in a feed-forward loop. Mol Endocrinol. 2015;29(2):213–23.

Google Scholar 

Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes. 2008;57(5):1246–53.

Google Scholar 

Yu Y, He J, Li S, Song L, Guo X, Yao W, et al. Fibroblast growth factor 21 (FGF21) inhibits macrophage-mediated inflammation by activating Nrf2 and suppressing the NF-κB signaling pathway. Int Immunopharmacol. 2016;38:144–52.

Google Scholar 

Salminen A, Kaarniranta K, Kauppinen A. Integrated stress response stimulates FGF21 expression: systemic enhancer of longevity. Cell Signal. 2017;40:10–21.

Google Scholar 

Sonoda J, Chen MZ, Baruch A. FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases. Horm Mol Biol Clin Investig. 2017;30(2):20170002.

Google Scholar 

Meigs JB, Wilson PW, Fox CS, Vasan RS, Nathan DM, Sullivan LM, et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab. 2006;91(8):2906–12.

Google Scholar 

Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56(14):1113–32.

Google Scholar 

Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110(10):1245–50.

Google Scholar 

Bobbert T, Schwarz F, Fischer-Rosinsky A, Pfeiffer AF, Möhlig M, Mai K, et al. Fibroblast growth factor 21 predicts the metabolic syndrome and type 2 diabetes in Caucasians. Diabetes Care. 2013;36(1):145–9.

Google Scholar 

Choi JR, Kim JY, Park IH, Huh JH, Kim KW, Cha SK, et al. Serum fibroblast growth factor 21 and new-onset metabolic syndrome: KoGES-ARIRANG study. Yonsei Med J. 2018;59(2):287–93.

Google Scholar 

Ong KL, McClelland RL, Allison MA, Kokkinos J, Wu BJ, Barter PJ, et al. Association of elevated circulating fibroblast growth factor 21 levels with prevalent and incident metabolic syndrome: the multi-ethnic study of atherosclerosis. Atherosclerosis. 2019;281:200–6.

Google Scholar 

Lamster IB, Pagan M. Periodontal disease and the metabolic syndrome. Int Dent J. 2017;67(2):67–77.

Google Scholar 

Gobin R, Tian D, Liu Q, Wang J. Periodontal diseases and the risk of metabolic syndrome: an updated systematic review and meta-analysis. Front Endocrinol (Lausanne). 2020;11:336.

Google Scholar 

Page RC, Kornman KS. The pathogenesis of human periodontitis: an introduction. Periodontol. 2000;1997(14):9–11.

Google Scholar 

Preshaw PM, Alba AL, Herrera D, Jepsen S, Konstantinidis A, Makrilakis K, et al. Periodontitis and diabetes: a two-way relationship. Diabetologia. 2012;55(1):21–31.

Google Scholar 

Sanz M, Marco Del Castillo A, Jepsen S, Gonzalez-Juanatey JR, D'Aiuto F, Bouchard P, et al. Periodontitis and cardiovascular diseases: consensus report. J Clin Periodontol. 2020;47(3):268–88.

Google Scholar 

Amr E, Mostafa R, Shaker O. Possible role of gingival crevicular fluid levels of Chemerin and fibroblast growth factor 21 as biomarkers of periodontal disease in diabetic and non-diabetic patients. A diagnostic accuracy study. Adv. Dent J. 2019;1(2):52–63.

Google Scholar 

Wang S, Liu J, Zhang J, Lin J, Yang S, Yao J, et al. Glycemic control and adipokines after periodontal therapy in patients with type 2 diabetes and chronic periodontitis. Braz Oral Res. 2017;31:e90.

Google Scholar 

Panezai J, Altamash M, Engstrӧm PE, Larsson A. Association of glycated proteins with inflammatory proteins and periodontal disease parameters. J Diabetes Res. 2020;2020:6450742.

Google Scholar 

Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; world heart federation; international atherosclerosis society; and International Association for the Study of obesity. Circulation. 2009;120(16):1640–5.

Google Scholar 

Löe H. The gingival index, the plaque index and the retention index systems. J Periodontol. 1967;38(6):610–6.

Google Scholar 

Tonetti MS, Greenwell H, Kornman KS. Staging and grading of periodontitis: framework and proposal of a new classification and case definition. J Clin Periodontol. 2018;45(suppl 20):S149–61.

Google Scholar 

Gaich G, Chien JY, Fu H, Glass LC, Deeg MA, Holland WL, et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 2013;18(3):333–40.

Google Scholar 

Talukdar S, Zhou Y, Li D, Rossulek M, Dong J, Somayaji V, et al. Long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects. Cell Metab. 2016;23(3):427–40.

Google Scholar 

Jin QR, Bando Y, Miyawaki K, Shikama Y, Kosugi C, Aki N, et al. Correlation of fibroblast growth factor 21 serum levels with metabolic parameters in Japanese subjects. J Med Investig. 2014;61(1–2):28–34.

Google Scholar 

Gao RY, Hsu BG, Wu DA, Hou JS, Chen MC. Serum fibroblast growth factor 21 levels are positively associated with metabolic syndrome in patients with type 2 diabetes. Int J Endocrinol. 2019;2019:5163245.

Google Scholar 

Tyynismaa H, Raivio T, Hakkarainen A, Ortega-Alonso A, Lundbom N, Kaprio J, et al. Liver fat but not other adiposity measures influence circulating FGF21 levels in healthy young adult twins. J Clin Endocrinol Metab. 2011;96(2):E351–5.

Google Scholar 

Schlein C, Talukdar S, Heine M, Fischer AW, Krott LM, Nilsson SK, et al. FGF21 lowers plasma triglycerides by accelerating lipoprotein catabolism in white and brown adipose tissues. Cell Metab. 2016;23(3):441–53.

Google Scholar 

Li JY, Wang N, Khoso MH, Shen CB, Guo MZ, Pang XX, et al. FGF-21 elevated IL-10 production to correct LPS-induced inflammation. Inflammation. 2018;41(3):751–9.

Google Scholar 

Iwasaki M, Sato M, Minagawa K, Manz MC, Yoshihara A, Miyazaki H. Longitudinal relationship between metabolic syndrome and periodontal disease among Japanese adults aged ≥70 years: the Niigata study. J Periodontol. 2015;86(4):491–8.

Google Scholar 

Furuta M, Liu A, Shinagawa T, Takeuchi K, Takeshita T, Shimazaki Y, et al. Tooth loss and metabolic syndrome in middle-aged Japanese adults. J Clin Periodontol. 2016;43(6):482–91.

Google Scholar 

Kaye EK, Chen N, Cabral HJ, Vokonas P, Garcia RI. Metabolic syndrome and periodontal disease progression in men. J Dent Res. 2016;95(7):822–8.

Google Scholar 

Souza ML, Massignan C, Glazer Peres K, Aurélio PM. Association between metabolic syndrome and tooth loss: a systematic review and meta-analysis. J Am Dent Assoc. 2019;150(12):1027–39.e7.

Google Scholar 

Pejcic A, Kesic LJ, Milasin J. C-reactive protein as a systemic marker of inflammation in periodontitis. Eur J Clin Microbiol Infect Dis. 2011;30(3):407–14.

Google Scholar 

留言 (0)

沒有登入
gif